1.Genetic diagnosis of non-classical 21-hydroxylase deficiency by the new nanopore sequencing detection method
Yanjie XIA ; Peng DAI ; Huikun DUAN ; Panlai SHI ; Shanshan GAO ; Xueyu GUO ; Ning LIU ; Xiangdong KONG
Chinese Journal of Laboratory Medicine 2023;46(1):74-80
Objective:To summarize initial experience of applying nanopore third-generation sequencing detection method (nanopore sequencing) for genetic diagnosis of non-classical 21 hydroxylase deficiency (NC 21-OHD), and to explore its performance and application prospects.Methods:Clinical data of the two NC 21-OHD patients, who were hospitalized at the First Affiliated Hospital of Zhengzhou University in May 2019, were collected. Peripheral venous blood was collected and genome DNA extracted. Genetic variants was detected by nanopore sequencing and underwent bioinformatic analysis. Pathogenetic mutations in CYP21A2 gene were validated with PCR-sanger sequencing in the two patients and their parents.Results:The average reads length and sequence depth in the patient one was 12, 792 bp and 27.19×. The average reads length and sequence depth in the patient two was 13, 123 bp and 21.34×. Compound variants of c.293-13C>G/c.844G>T (p.Val282Leu) and c.332_339delGAGACTAC (p.Gly111Valfs)/c.844G>T (p.Val282Leu) were detected in these two patients, which were consistent with clinical phenotype of NC 21-OHD. Further analysis showed that c.293-13C>G mutation was inherited from her father and c.844G>T (p.Val282Leu) mutation was inherited from her mother for the patient one. The c.844G>T (p.Val282Leu) mutation was inherited from her father and c.332_339delGAGACTAC (p.Gly111Valfs) mutation from her mother.Conclusions:The heterozygous mutations in CYP21A2 gene are the cause of NC 21-OHD in these two patients. Nanopore sequencing technique is a reliable new detection method for patients with NC 21-OHD.
2.Research progress on metformin in the treatment for malignant tumors
Xueyu DUAN ; Binbin LIAO ; Lei LI ; Dingcai ZHANG ; Ruixiang CHEN ; Xiaobo LIU
China Pharmacy 2024;35(15):1915-1922
In recent years, the potential anti-tumor effects of metformin have attracted widespread attention in the field of cancer treatment. This article summarizes the research progress of metformin in the treatment of malignant tumors,finding its potential application in the treatment of malignant tumors in the digestive system (biliary tract cancer,gastric cancer,esophagus cancer,colorectal cancer,pancreatic cancer,liver cancer) and reproductive system (prostate cancer,ovarian cancer,breast cancer, cervical cancer),non-small cell lung cancer,renal cell carcinoma,and melanoma. Metformin can inhibit the proliferation of tumor cells and extend the overall survival of patients. Its mechanisms of action include,but are not limited to,inhibiting the activity of mitochondrial complex Ⅰ,activating adenosine monophosphate-activated protein kinase/p53 signaling pathway,and blocking the cell cycle. Additionally,the combined use of metformin with chemotherapy drugs has shown potential for reducing toxicity and enhancing efficacy. It can enhance the sensitivity of biliary tract cancer,ovarian cancer,and melanoma cells to chemotherapy drugs, improve the drug resistance of gastric and colorectal cancer cells to chemotherapy,and reduce the toxic reactions of breast cancer patients during chemotherapy. Metformin is also used as an immunomodulator,applied in the immunotherapy of patients with esophagus cancer,colorectal cancer,cervical cancer,non-small cell lung cancer,and melanoma.
3.Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2− advanced or metastatic breast cancer: A network meta-analysis
Yanjiao PU ; Hui LI ; Wei CHEN ; Xueyu DUAN ; Chunmei CHEN ; Rui WU ; Xuechang WANG
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(06):830-838
Objective To compare the efficacy and safety of different cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced or metastatic breast cancer. Methods Randomized controlled trials (RCTs) on CDK4/6i for the treatment of HR+/HER2− metastatic or advanced breast cancer were retrieved from databases including PubMed, EMbase, Web of Science, The Cochrane Library, CNKI, Wanfang, VIP, and SinoMed, with the search period ranging from database inception to August 2023. Bayesian network meta-analysis was conducted using R 4.2.0 software. Results A total of 18 RCTs from 25 articles, involving 8 031 patients and 11 treatment regimens, were included. There was no significant difference in progression-free survival (PFS) or overall survival (OS) among different CDK4/6i+ET combinations. The highest cumulative probability for PFS was observed with dalpiciclib (DAL)+fulvestrant (FUL), while ribociclib (RIB)+FUL ranked first for OS. In terms of efficacy, abemaciclib (ABE)+aromatase inhibitors (AI) and ABE+FUL ranked first in objective response rate and clinical benefit rate, respectively. Regarding safety, statistically significant difference in grade 3-4 adverse events was observed among certain types of CDK4/6i (P<0.05). Conclusion Current evidence suggests that CDK4/6i+ET is superior to ET alone for the treatment of HR+/HER2− advanced/metastatic breast cancer. Different CDK4/6i+ET combinations demonstrate comparable or similar efficacy; however, the incidence of adverse reactions is higher with combination therapy. Treatment regimens should be selected based on individual conditions.
4.Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3.
Tian LU ; Yong LI ; Wenchao LU ; Twgm SPITTERS ; Xueyu FANG ; Jun WANG ; Simian CAI ; Jing GAO ; Yanting ZHOU ; Zhe DUAN ; Huan XIONG ; Liping LIU ; Qi LI ; Hualiang JIANG ; Kaixian CHEN ; Hu ZHOU ; Hua LIN ; Huijin FENG ; Bing ZHOU ; Christopher L ANTOS ; Cheng LUO
Acta Pharmaceutica Sinica B 2021;11(10):3206-3219
The TEA domain (TEAD) family proteins (TEAD1‒4) are essential transcription factors that control cell differentiation and organ size in the Hippo pathway. Although the sequences and structures of TEAD family proteins are highly conserved, each TEAD isoform has unique physiological and pathological functions. Therefore, the development and discovery of subtype selective inhibitors for TEAD protein will provide important chemical probes for the TEAD-related function studies in development and diseases. Here, we identified a novel TEAD1/3 covalent inhibitor (DC-TEADin1072) with biochemical IC